Why is AstraZeneca stock down today?

Traders Union
All News
Financial News
AstraZeneca drops 1.32% after Wainua trial miss

Highlights

AstraZeneca's phase 3 trial failure for Wainua in ATTR-CM sharply erodes expectations for cardiovascular portfolio growth and new revenue streams.
Positive U.S. appeals court decision on Tagrisso patents supports continued exclusivity, reinforcing medium-term lung cancer franchise revenue protection.
Bearish technical outlook prevails as shares trade below key averages, with heightened downside risk and an expected GBX12,221–14,134 range.

Revenue confidence hit as heart drug trial fails but patent win aids

AstraZeneca reported on July 9, 2026, that its late-stage clinical trial for the heart disease drug Wainua (eplontersen), developed in partnership with Ionis Pharmaceuticals, did not achieve its primary endpoint for treating ATTR-CM, according to CNBC and Gurufocus. The outcome significantly diminishes expectations for new revenue streams in the cardiovascular portfolio and contributed to a substantial decline in market capitalization, underlining deteriorating investor confidence in future pipeline earnings. On the same day, AstraZeneca secured a favorable U.S. appeals court ruling on patent claims for its lung cancer drug Tagrisso, supporting continued exclusivity and future revenue protection, as reported by Gurufocus.

Seller momentum dominates as price stays under technical resistance

On the one-hour chart, AZN is trading below the MA-20 at GBX13,694 and the MA-50 at GBX14,066, while the daily chart shows price also below the MA-200 at GBX13,778. The Ichimoku Kijun stands at GBX13,433, marking immediate resistance. Short-term indicators confirm ongoing negative momentum: the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) are both in sell territory, while the Relative Strength Index (RSI) reads 41.02—closer to the lower end, but not yet oversold. Stochastic RSI and Commodity Channel Index (CCI) both register as neutral, and the Bull/Bear Power shows intraday oversold conditions and seller dominance. The Awesome Oscillator is neutral and does not currently provide a strong trend signal. Despite some neutral oscillator readings, the dominant technical signals remain negative.

Downside risk favored amid heightened volatility and uncertain breakout

Looking ahead to the next several days, AZN is expected to trade within a range of GBX12,221 to GBX14,134, reflecting its recent volatility band. Downside risk is more probable in the short term, with a 60% likelihood of further declines versus a 40% chance of recovery. The baseline scenario anticipates price action remaining largely sideways between these levels. A bullish case would only form if the stock breaks decisively above immediate resistance, while a deeper selloff may emerge should price fall below the lower boundary of current support.

Anton Kharitonov, analyst at Traders Union, sees AstraZeneca under clear short-term pressure. Negative clinical trial news weighs more than the legal win. Technical momentum and sentiment both point down while the price remains below key resistances. "Until AZN reclaims GBX13,433, I see more risk to the downside and would remain defensive here."

Previously it was reported that AstraZeneca faced renewed bearish momentum following setbacks in its clinical pipeline and missed expectations for key drug trials. The latest data reinforces this negative outlook amid ongoing technical weakness, making the stock’s response to any sustained move above GBX13,433 a critical signal for a potential shift in short-term direction.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.